Navigation Links
Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
Date:10/28/2008

Study results to be presented at 2008 ICAAC/IDSA Joint Meeting

ROCKVILLE, Md., Oct. 28 /PRNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products to treat infectious diseases of epidemic potential, announces the successful demonstration of synergistic activities and improvement of minimal inhibitory concentration (MIC) resulting from in vitro combination studies of Sequella lead TB drug candidate, SQ109, and Tibotec's lead TB drug candidate, TMC207. Both drug candidates are currently undergoing human clinical studies.

Results from these studies were presented on October 28th at the Interscience Conference on Anti-Microbial Agents and Chemotherapeutics (ICAAC) and Infectious Disease Society of America (IDSA) joint meeting in Washington, DC.

The collaboration between Sequella and Tibotec was designed to investigate in vitro interactions of SQ109 for synergistic, additive, or antagonistic activity in the presence of TMC207, using a number of clinical and laboratory strains of both drug sensitive and drug resistant M. tuberculosis (MTB). In vitro interactions investigated included synergy studies, rate of killing, post antibiotic effect and intracellular activity against MTB in macrophages.

There were no antagonistic activities observed in any combination studies. SQ109 and TMC207 in combination were either synergistic or additive with the various MTB strains and showed increased rate of killing, enhanced post antibiotic effect and intracellular killing activity. Results showed that the SQ109 and TMC207 drug combination was extraordinary potent, with greater than 90% kill of MTB as early as 1 day after drug combination exposure.

Dr. Carol Nacy, CEO of Sequella said, "We are very pleased to be collaborating with Tibotec, a world renowned product development organization, and we look forward to our continuing partnership to examine these important drug synergies in animal models
'/>"/>

SOURCE Sequella, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Topical Treatment for Cold Sores Achieves Efficacy of Oral Drugs; Represents Paradigm Shift in the Treatment of Skin Infections
2. Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference
3. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
4. Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis
5. Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
6. Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress
7. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
8. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
9. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
10. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
11. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 Rock Creek Pharmaceuticals, ... it has initiated the development of its lead molecule, ... that it has selected Quotient Clinical, The Translational Pharmaceutics ... (UK) to run its early development programs. ... Application (CTA) by the end of the third quarter ...
(Date:7/31/2014)... Calif. , July 31, 2014 Lazarus ... of novel interventional devices to facilitate removal of blood ... Proceeds from the financing will support EU commercialization of ... filings for the Lazarus ReCover™ and Lazarus Cover™ in ... "This financing reflects investor confidence in the value of ...
(Date:7/31/2014)... and VIENNA , July 31, 2014 ... press conference in New York results ... vaccine against Parkinson,s disease. PD01A is the first therapy against ... clinical testing. The Michael J. Fox Foundation for ... million grant, and presented at the press conference on the ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Lazarus Effect Closes $5 Million Financing 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4
(Date:8/1/2014)... The North America Sports Drink Market report ... with analysis and forecast of revenue. The Sports Drink Market ... million in 2012 to $6,243 million by 2018, at a ... the TOC of the North America Sports Drink market report, ... also provides a glimpse of the segmentation in the North ...
(Date:8/1/2014)... The Gerontological Society of America (GSA) ... of aging has chosen Carole B. Lewis, PT, ... 2014 recipient of the Excellence in Rehabilitation of Aging ... to acknowledge outstanding contributions in the field of rehabilitation. ... teaching or patient care, or publications that may include ...
(Date:8/1/2014)... Home Care Assistance of Cincinnati , ... to be recognized as a 2014 Best of Home Care ... care providers who rank in the top 50th percentile in ... interviews conducted by Home Care Pulse. , “The Best ... the best of the best!” says Home Care Pulse Founder ...
(Date:8/1/2014)... York City, NY (PRWEB) August 01, 2014 ... for two incomes, and the convenience of processed, microwavable dinners, ... epidemic. Diet Doc does not offer patients a mere quick ... about helping everyone, in any part of the country, get ... that if they offer patients the tools and education on ...
(Date:8/1/2014)... This week marks a significant milestone for ... of paying commissions to its independent distributor sales force. ... 2005 total $1,405,954,677.06. , MonaVie distributors can be found ... commissions in 18 different currencies, including: AUD, EUR, BRL, ... USD, SGD, KRW, TWD, THB and GBP. , ...
Breaking Medicine News(10 mins):Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Lewis to receive GSA's 2014 Excellence in Rehabilitation of Aging Persons Award 2Health News:Cincinnati Senior Care Company Receives 2014 Best of Home Care® Employer of Choice Award 2Health News:Diet Doc Medical Weight Loss Programs Announces Diet Plans That Melt Excess Fat Rapidly While Teaching Patients How to Avoid Obesity 2Health News:Diet Doc Medical Weight Loss Programs Announces Diet Plans That Melt Excess Fat Rapidly While Teaching Patients How to Avoid Obesity 3Health News:MonaVie Records 500th Commission Week, Having Paid Out More Than $1.4B in Distributor Commissions 2
... of Chemistry at Stevens Institute of Technology, recently ... of Michigan. Named in honor of pioneer pharmaceutical ... established to recognize outstanding lifetime achievements in medicinal ... lecture, "Drug Discovery Lessons Learned," was delivered ...
... News) -- Early adolescence is the time that patients with ... pediatric to adult medical care, says a new American Heart ... birth, is the most common type of birth defect. Most ... The majority of children born with a congenital heart ...
... lab tests and imaging can sometimes help diagnose juvenile ... history are the most valuable tools in identifying this ... Journal of the American Academy of Orthopaedic Surgeons ... evaluations and imaging studies meant to screen for juvenile ...
... Turmeric, a bright yellow spice from south Asia belonging ... curries and ancient wisdom suggests that it,s also ... laboratory, Tel Aviv University researchers have discovered that turmeric,s ... highly toxic anti-inflammatory drugs used to fight colon cancer ...
... Amanda Gardner HealthDay Reporter , TUESDAY, March ... or young adult raises your risk of having psychotic ... "This cements much more firmly the reality that ... with the other genetic, environmental and socioeconomic risk factors, ...
... March 2 (HealthDay News) -- A daytime nap of at least ... protect their heart, a new study suggests. The finding comes ... two groups. One group had an hour-long period during the day ... groups were given a mental stress test. Blood pressure and ...
Cached Medicine News:Health News:Stevens' Dr. A. K. Ganguly receives Topliss Award Lecture from University of Michigan 2Health News:Teens With Congenital Heart Disease Need Help Moving to Adult Care 2Health News:Joint pain in children: Is it just a sore knee, or ... ? 2Health News:Fighting cancer at your local Indian restaurant 2Health News:Pot Use in Youth Ups Risk of Psychotic Symptoms in Later Life 2
Standard Deflectable Catheters...
Fixed and steerable lumen diagnostic mapping catheters are offered in a variety of catheter configurations...
The Polaris-DX steerable diagnostic catheter is designed for comfort and ergonomic handling during mapping procedures....
Sophisticated DecaPolar Catheters provide enhanced recording and mapping quality....
Medicine Products: